NCT00363350View on ClinicalTrials.gov

Rituximab Treatment in Sjogren's Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Sjogren's Syndrome
Interventions
DRUG

rituximab (anti-CD20)

2 infusions of 1000 mg

Trial Locations (1)

9700 RB

University Medical Centre Groningen, Groningen

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

University Medical Center Groningen

OTHER

NCT00363350 - Rituximab Treatment in Sjogren's Syndrome | Biotech Hunter | Biotech Hunter